This page shows the latest simeprevir news and features for those working in and with pharma, biotech and healthcare.
On the downside, hepatitis C therapy Olysio/Sovriad (simeprevir) continued its decline in the face of strong competition in the marketplace from Gilead and AbbVie, falling 86% to just $32m in
to $8.1bn despite heavy competition to hepatitis C therapies Olysio (simeprevir) and Incivo (telaprevir) from Gilead and AbbVie.
disease and arthritis drug Remicade (infliximab) and Olysio (simeprevir) for hepatitis C virus offset by growth in newer products.
toll on J&J's Olysio (simeprevir) and Incivek (telaprevir) products.
J&J already has one new-generation oral HCV therapy on the market, its NS3/4A protease inhibitor Olysio (simeprevir), but could do with additional drugs in its portfolio in order
simeprevir), while Merck &Co also has a new treatment in the works.
More from news
Approximately 9 fully matching, plus 32 partially matching documents found.
Meanwhile, for Olysio (simeprevir) - one of several new oral drugs that mark a major step forward in hepatitis C treatment - it was an innovative 'pay-if-you-clear' scheme that persuaded
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
simeprevir). “Medivir is an attractive company in an exciting phase of its development following the successful market introduction of simeprevir,” he said.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Gilead’s interferon-free product sofosbuvir and Johnson &Johnson’s simeprevir appear to lead the field – receiving the highest levels of spontaneous and prompted awareness. ... However, Abbvie’s products ABT 267, ABT 333 and ABT 450 remain
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...